Labcorp Buys Myriad Genetics’ Vectra Autoimmune Test Business
Executive Summary
Labcorp has agreed to pay $150m in cash for Myriad Genetics’ autoimmune business, one of three major units Myriad is unloading as it tries to narrow its focus to oncology, women's health and mental health diagnostics.
You may also be interested in...
Exec Chat: Myriad CEO Speaks On Defining Its Market And Differentiating Its Offerings
Myriad CEO Paul Diaz talked to Medtech Insight about how Innovation and investment are two major drivers of differentiation in precision medicine.
Q2 Dealmaking Statistics: Medtech And Diagnostics M&A And Alliance Activity, April-June 2021
During the second quarter of 2021, device company M&A values reached $2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.4bn.
PerkinElmer To Buy UK-Based Immunodiagnostics For $155M
PerkinElmer will add chemiluminescence products in endocrinology, autoimmunity and diagnostics to its portfolio with the planned buyout of Immunodiagnostics.